Jade Biosciences (JBIO) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Does the media refer more to CASI or JBIO?

In the previous week, Jade Biosciences had 4 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 6 mentions for Jade Biosciences and 2 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.93 beat Jade Biosciences' score of -0.13 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is CASI or JBIO more profitable?

Jade Biosciences has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Jade Biosciences' return on equity of -72.83% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
Jade Biosciences	N/A	-72.83%	-67.90%

Do insiders & institutionals hold more shares of CASI or JBIO?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 24.9% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, CASI or JBIO?

CASI Pharmaceuticals has higher revenue and earnings than Jade Biosciences. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	1.03	-$39.26M	-$2.55	-0.93
Jade Biosciences	N/A	N/A	-$69.63M	-$30.33	-0.24

Which has more volatility and risk, CASI or JBIO?

CASI Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Do analysts recommend CASI or JBIO?

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 68.07%. Jade Biosciences has a consensus target price of $16.00, suggesting a potential upside of 117.39%. Given Jade Biosciences' higher possible upside, analysts plainly believe Jade Biosciences is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jade Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Jade Biosciences beats CASI Pharmaceuticals on 9 of the 14 factors compared between the two stocks.